Eikon Therapeutics Inc.

5 trials 3 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

0 Completed trials

18 Countries active

8 Unique IMPs

N/A Results reported

Phase II/III

Phase II

Phase I/II

Phase I (FiH)

Phase II/III: 1 Phase II: 1 Phase I/II: 1 Phase I (FiH): 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Top IMPs

RESIQUIMOD SULFATE 2 EIK1003 1 EIK1004 BIS-TARTRATE 1 EIK1005 SODIUM 1

All trials

5 total

A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending

2025-525013-23-00 Phase II 6 countries RESIQUIMOD SULFATE
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab… Pending

2026-525248-13-00 Phase I/II 8 countries EIK1005 SODIUM
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Phase II/III 15 countries RESIQUIMOD SULFATE
A Phase 1/2, open-label, multicenter, dose-escalation, and dose‑optimization study to evaluate the safety, tolerability, and activity of EIK… Recruiting

2024-520395-99-00 Phase I (FiH) 4 countries EIK1004 BIS-TARTRATE
A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting

2023-509230-19-00 Phase I (FiH) 3 countries EIK1003

Showing 1–5 of 5 trials

← All sponsors A–Z